A Nature study uncovers a previously unknown pathway that regulates TFEB, a master controller of lysosomal function and cellular recycling. By identifying druggable targets upstream of TFEB, the research opens new opportunities for treating rare genetic diseases, cancer and other disorders linked to lysosomal dysfunction.

Finding a few tumor cells hidden among billions of blood cells is one of the biggest challenges in liquid biopsy. Circulating tumor cells (CTCs), which break away from primary tumors and enter the bloodstream, can provide important clues about cancer progression and treatment response. However, their extremely low abundance—often only one to ten cells among a billion blood cells—makes them difficult to isolate and accurately identify.

In a new study published in Biomedical Analysis, researchers from Taiyuan University of Technology and Shanxi Bethune Hospital developed a new strategy that combines a microfluidic chip with artificial intelligence to address this challenge. The platform first separates tumor cells from surrounding blood cells according to their physical differences, then uses deep learning to identify the enriched cells from ordinary microscope images. This approach provides a new route toward simpler, less label-dependent CTC analysis.